Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report

Cellular Oncology

Volumn 38, Issue 6, 2015, Pages 485-491

  You, Yanjie ^a,b,c   Li, Haijun ^d   Qin, Xin ^e   Zhang, Yinpo ^a   Song, Wengang ^a   Ran, Yonggang ^f   Gao, Fenglan ^a  

^a Pathological Examinations and Research Center   (China)

^b Luohe Medical College   (China)

^c Luohe Key Laboratory of Medical Bioengineering   (China)

^d Department of Radiation Oncology The Second People s Hospital of Neijiang City   (China)

^e HUBEI UNIVERSITY OF ARTS AND SCIENCE   (China)

^f Bethune Medical NCO School   (China)

Author keywords

Breast cancer; CDK10; Immunohistochemistry; Prognosis

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 10; FORMALDEHYDE; PARAFFIN; UNCLASSIFIED DRUG; CDK10 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; WESTERN BLOTTING; BIOSYNTHESIS; BREAST TUMOR; DISEASE FREE SURVIVAL; DOWN REGULATION; FEMALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BLOTTING, WESTERN; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASES; DISEASE-FREE SURVIVAL; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84947615281     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-015-0246-4     Document Type: Article

References (30)

1. L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015)
2. C.M. Perou, T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lønning, A.L. Børresen-Dale, P.O. Brown, D. Botstein, Molecular portraits of human breast tumours. Nature 406, 747–752 (2000)
3. S. Di Cosimo, J. Baselga, Management of breast cancer with targeted agents: importance of heterogeneity. Nat. Rev. Clin. Oncol. 7, 139–147 (2010)
4. J. Peppercorn, C.M. Perou, L.A. Carey, Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Investig. 26, 1–10 (2008)
5. S. Tabarestani, S.M. Ghaderian, H. Rezvani, R. Mirfakhraie, A. Ebrahimi, H. Attarian, J. Rafat, M. Ghadyani, H.A. Alavi, N. Kamalian, A. Rakhsha, E. Azargashb, Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification. Cell. Oncol. 37, 107–118 (2014)
6. A.H. Verschuur-Maes, C.B. Moelans, P.C. de Bruin, P.J. van Diest, Analysis of gene copy number alterations by multiplex ligation-dependent probe amplification in columnarcell lesions of the breast. Cell. Oncol. 37(147–154) (2014)
7. E. Yiannakopoulou, Etiology of familial breast cancer with undetected BRCA1 and BRCA2 mutations: clinical implications. Cell. Oncol. 37(1–8) (2014)
8. L.J. van’t Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao, H.L. Peterse, K. van der Kooy, M.J. Marton, A.T. Witteveen, G.J. Schreiber, R.M. Kerkhoven, C. Roberts, P.S. Linsley, R. Bernards, S.H. Friend, Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002)
9. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012)
10. E.A. Musgrove, R.L. Sutherland, Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9, 631–643 (2009)
11. C.A. Hudis, Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39–51 (2007)
12. F. Bullrich, T.K. MacLachlan, N. Sang, T. Druck, M.L. Veronese, S.L. Allen, N. Chiorazzi, A. Koff, K. Heubner, C.M. Croce et al., Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res. 55, 1199–1205 (1995)
13. J. Crawford, L. Ianzano, M. Savino, S. Whitmore, A.M. Cleton-Jansen, C. Settasatian, M. D’apolito, R. Seshadri, J.C. Pronk, A.D. Auerbach, P.C. Verlander, C.G. Mathew, A.J. Tipping, N.A. Doggett, L. Zelante, D.F. Callen, A. Savoia, The PISSLRE gene: structure, exon skipping, and exclusion as tumor suppressor in breast cancer. Genomics 56, 90–97 (1999)
14. E. Iorns, N.C. Turner, R. Elliott, N. Syed, O. Garrone, M. Gasco, A.N. Tutt, T. Crook, C.J. Lord, A. Ashworth, Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13, 91–104 (2008)
15. C.J. Lord, E. Iorns, A. Ashworth, Dissecting resistance to endocrine therapy in breast cancer. Cell Cycle 7, 1895–1898 (2008)
16. P. Khanal, H.J. Yun, S.C. Lim, S.G. Ahn, H.E. Yoon, K.W. Kang, R. Hong, H.S. Choi, Proyl isomerase Pin1 facilitates ubiquitin-mediated degradation of cyclin-dependent kinase 10 to induce tamoxifen resistance in breast cancer cells. Oncogene 31, 3845–3856 (2012)
17. C.W. Yeh, S.H. Kao, Y.C. Cheng, L.S. Hsu, Knockdown of cyclin-dependent kinase 10 (cdk10) gene impairs neural progenitor survival via modulation of raf1a gene expression. J. Biol. Chem. 288, 27927–27939 (2013)
18. J.H. Yu, X.Y. Zhong, W.G. Zhang, Z.D. Wang, Q. Dong, S. Tai, H. Li, Y.F. Cui, CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. Oncol. Rep. 27, 1266–1276 (2012)
19. X.Y. Zhong, X.X. Xu, J.H. Yu, G.X. Jiang, Y. Yu, S. Tai, Z.D. Wang, Y.F. Cui, Clinical and biological significance of Cdk10 in hepatocellular carcinoma. Gene 498, 68–74 (2012)
20. Y. You, W. Yang, Z. Wang, H. Zhu, H. Li, C. Lin, Y. Ran, Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas. Cell. Oncol. 36, 323–331 (2013)
21. C.Q. Hong, F. Zhang, Y.J. You, W.L. Qiu, A.E. Giuliano, X.J. Cui, G.J. Zhang, Y.K. Cui, Elevated C1orf63 expression is correlated with CDK10 and predicts better outcome for advanced breast cancers: a retrospective study. BMC Cancer 15, 548 (2015)
22. Y. You, W. Yang, X. Qin, F. Wang, H. Li, C. Lin, W. Li, C. Gu, Y. Zhang, Y. Ran, ECRG4 acts as a tumor suppressor and as a determinant of chemotherapy resistance in human nasopharyngeal carcinoma. Cell. Oncol. 38, 205–14 (2015)
23. A.S. Howell, D.J. Lew, Morphogenesis and the cell cycle. Genetics 190(1), 51–77 (2012)
24. S. Mahale, S.B. Bharate, S. Manda, P. Joshi, P.R. Jenkins, R.A. Vishwakarma, B. Chaudhuri, Antitumour potential of BPT: a dual inhibitor of cdk4 and tubulin polymerization. Cell Death Dis. 6, e1743 (2015)
25. T. VanArsdale, C. Boshoff, K.T. Arndt, R.T. Abraham, Molecular pathways: targeting the cyclin D-CDK4/6 axis for cancer treatment. Clin. Cancer Res. 21, 2905–2910 (2015)
26. Z. Feng, S. Xu, M. Liu, Y.X. Zeng, T. Kang, Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Cancer Lett. 297, 190–197 (2010)
27. V.J. Guen, C. Gamble, M. Flajolet, S. Unger, A. Thollet, Y. Ferandin, A. Superti-Furga, P.A. Cohen, L. Meijer, P. Colas, CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proc. Natl. Acad. Sci. U. S. A. 110, 19525–19530 (2013)
28. G. Heller, B. Ziegler, A. Brandstetter, S. Novak, M. Rudas, G. Hennig, M. Gehrmann, T. Acht, S. Zöchbauer-Müller, M. Filipits, CDK10 is not a target for aberrant DNA methylation in breast cancer. Anticancer Res. 29, 3939–3944 (2009)
29. A. Dhasarathy, M. Kajita, P.A. Wade, The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol. Endocrinol. 21, 2907–2918 (2007)
30. Y. Ran, S. Wu, Y. You, Demethylation of E-cadherin gene in nasopharyngeal carcinoma could serve as a potential therapeutic strategy. J. Biochem. 149, 49–54 (2011)